Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

China Medicine Corp. Drops on Improved Q1

publication date: May 13, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China Medicine Corporation said Q1 revenues rose 43% to $10.1 million while net income rose a more modest 11% to $1.3 million (non-GAAP) or 9 cents per share, fully diluted. A charge related to the fair value of warrants took GAAP earnings down to $.55 million, an eps of 4 cents. Investors were not impressed. Shares of China Medicine fell 17%, slipping 35 cents lower to $1.75 in mid-session. At this price, the company has a market capitalization of just $27 million. More details...

Stock Symbol: (OTCBB: CHME)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors